tbuckley/cabot-search huggingface dataset:
Prognostic significance of tumour size in T1 breast cancer patients with no axillary lymph node involvement: Analysis of 1857 patients
Authors: E. Fiorio, A. Mercanti, A. Auriemma, M. Giovannini, M. Mandarà, M. Pavarana, A. Caldara, R. Micciolo, G. L. Cetto, A. Molino
Journal: Journal of Clinical Oncology (2005)

771 Background: Tumour size and node involvement are the most important prognostic factors in breast cancer (BC). Node-negative (N-) and T1 BCs usually have a better prognosis, but some of these patients experience a recurrence and die of systemic disease. Materials and Methods: We studied 1857 patients with invasive N- and T1 BCs to evaluate the importance of the tumour diameter and correlated it with pathological, biological and clinical parameters in order to define a subgroup of patients at higher risk of recurrence. T1a, T1b and T1c tumours were correlated with grading (G1, G2, G3), vascular invasion (VI) (positive vs negative), ER and PgR (positive vs negative), Ki-67 proliferative index (low 0–10%; intermediate 11–25%; high 26–100%), mammary family history (MF) (positive vs negative) and type of diagnosis (asymptomatic vs symptomatic). The data were analysed using the chi-squared test. Results: The larger lesions were associated with poor prognostic factors such as G3 (76.1% in T1c vs 18.1% in T1b vs 5.8% in T1a p<0.001), VI (77.6% in T1c vs 19.6% in T1b vs 2.8% in T1a p<0.001), ER- (71.3% in T1c vs 25.4% in T1b vs 3.3% in T1a p=0.03) high Ki-67 levels (80.7% in T1c vs 14.9% in T1b vs 4.4% in T1a p<0.001), MF+ (57.5% in T1c vs 33.5% in T1b vs 9% in T1a p=0.01) and a symptomatic diagnosis (74.7% in T1c vs 22.4% in T1b vs 2.9% in T1a p<0.001). No association was found with PgR. Conclusion: Our results show that, among the patients with N- and T1 BCs, the subgroup with T1c lesions correlates with most poor prognostic factors (G3, VI, ER-, higher Ki-67 levels, MF+ and a symptomatic diagnosis). As these patients are at high risk of recurrence, after good radical surgery, it is important to offer them adequate adjuvant therapy as a reasonable treatment option based on endocrine responsiveness. No significant financial relationships to disclose.
Abstract 4314: Loss of CYLD promotes cell migration through stabilized ALK5 in human oral squamous cell carcinoma cells.
Authors: Satoru Shinriki, Hirofumi Jono, Jian-Dong Li, Takuya Nakamura, Mitsuhiro Hayashi, Jianying Guo, Masanori Shinohara, Yukio Ando
Journal: Cancer Research (2013)

Abstract Five-year survival of patients with oral squamous cell carcinoma (OSCC) has not changed apparently for the past 30 years. Although cylindromatosis (CYLD) is thought as a potent tumor suppressor, its biological significances in malignancies are largely unknown. The aim of this study was to clarify the role of CYLD in OSCC progression. We investigated expression of CYLD in OSCC including intraepithelial neoplasia (IEN; n = 48) and invasive carcinomas (n = 133) tissues and normal oral mucosal tissues (n = 35) by immunohistochemistry. In addition, effects of CYLD knockdown by siRNA or its overexpression on OSCC progression using OSCC cell lines. Our immunohistochemical analyses revealed that CYLD expression was significantly reduced at invasive lesions in OSCC tissues whereas it was conserved in normal epithelium and IEN. In addition, lower CYLD expression was associated with poor overall survival in invasive OSCC. Accordingly, CYLD knockdown led to acquisition of mesenchymal state and increased migratory activity in OSCC cells. Interestingly, loss of CYLD enhanced TGFβR1 (ALK5) protein expression by promoting ALK5 stability while overexpression of wild-type CYLD downregulated ALK5. Furthermore, EMT-like changes induced by CYLD knockdown were completely blocked by a TGFβR1 kinase inhibitor in OSCC cells. These findings suggest that downregulation of CYLD promotes invasion through EMT-like changes via ALK5 stabilization in OSCC cells. Further studies for these mechanisms probably provide new insights into the TGFβ signal transduction in cancer and development of a novel therapy in OSCC. Citation Format: Satoru Shinriki, Hirofumi Jono, Jian-Dong Li, Takuya Nakamura, Mitsuhiro Hayashi, Jianying Guo, Masanori Shinohara, Yukio Ando. Loss of CYLD promotes cell migration through stabilized ALK5 in human oral squamous cell carcinoma cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4314. doi:10.1158/1538-7445.AM2013-4314
18F-FDG PET/CT Findings in Two Cases With Myelodysplastic Syndrome Accompanied by Behçet’s Disease
Authors: Kimiteru Ito, Kazuo Kubota
Journal: Clinical Nuclear Medicine (2016)

Recently, the co-occurrence of myelodysplastic syndrome (MDS) and Behçet's disease (BD) has been reported in association with trisomy 8 and HLA 51, with the pathology varying from vasculitis to acute neutrophilic inflammation. We report for the first time about imaging findings of F-fluorodeoxyglucose (FDG) positron emission/computed tomography (PET/CT) in 2 cases having MDS accompanied by BD. In these cases, 18 F-FDG PET/CT images clearly revealed high uptake by bone marrow in MDS and by genital aphthous or ileocecal ulcers in BD. F-FDG PET/CT may be the ideal modality for the detection of comorbidity of MDS and BD.
Abstract 1654: Cisplatin resistance is associated with autophagy in SPARC expressing medulloblastoma cells.
Authors: Padmavathi Pannuru, Ranadheer Dontula, Herbert Engelhard, Howard Ozer, Sajani S. Lakka
Journal: Cancer Research (2013)

Abstract Medulloblastoma is the most common malignant brain tumor in children and is associated with a poor outcome. Our previous studies indicate that SPARC expression suppressed medulloblastoma tumor growth in vitro and in vivo. We were interested in gaining further insight into the potential of SPARC expression as a novel approach to sensitize medulloblastoma to chemotherapeutic agents. In this study, we demonstrate that SPARC: expression resulted in enhanced resistance of cancer cells to cisplatin, a commonly used chemotherapeutic drug in the treatment of medulloblastoma. We also demonstrate that autophagy was involved in SPARC expression mediated resistance to cisplatin. We further demonstrated that suppression of autophagy by autophagy inhibitors, 3-methyladenosine (3MA) and small interfering RNAs (siRNAs) targeting Atg5 in SPARC expressed cells enhanced the sensitivity of medulloblastoma cells to cisplatin compared to cells treated with cisplatin alone. Moreover, sensitization to cisplatin by inhibition of autophagy is SPARC expressed cells was accompanied by induction of apoptosis indicating that suppression of autophagy indeed renders tumor cells more sensitive to cisplatin. Further we show overexpression of High mobility group box 1 (HMGB1 in SPARC expressed cells rendered medulloblastoma cells resistant to cell death; whereas depletion of HMGB1 using RNA interference suppressed autophagy and increased the sensitivity of medulloblastoma cells to cisplatin as assessed by microtubule-associated protein 1 light chain 3 (LC3) lipidation, redistribution of LC3 into cytoplasmic puncta, and accumulation of autophagosomes and autolysosomes. Further our data suggest a role for HMGB1 in the regulation of autophagy through the MEK-ERK pathway in SPARC over expressed cells. The results of our study revealed a new mechanism for enhancing cisplatin sensitivity in SPARC expressed cells. These findings have important clinical implications for the design of experimental treatment protocols for medulloblastoma. Citation Format: Padmavathi Pannuru, Ranadheer Dontula, Herbert Engelhard, Howard Ozer, Sajani S. Lakka. Cisplatin resistance is associated with autophagy in SPARC expressing medulloblastoma cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1654. doi:10.1158/1538-7445.AM2013-1654 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
Case 39-2014
Authors: Benjamin A. Nelson, Jess L. Kaplan, Chadi M. El Saleeby, Michael T. Lu, Eugene J. Mark
Journal: New England Journal of Medicine (2014)

A 9-year-old girl with Crohn's disease was admitted to this hospital because of abdominal pain and diarrhea. Abdominal imaging showed pulmonary nodules, some with necrotic centers. A diagnostic procedure was performed.
Silencing expression of Ras family GTPase homologues decreases inflammation and joint destruction in experimental arthritis
Authors: D de Launay, J Vreijling, J R F Abreu, M A van Maanen, M E Sanders, M J Vervoordeldonk, H Oerum, K Fluiter, P P Tak, K A Reedquist
Journal: Annals of the Rheumatic Diseases (2010)

Changes in expression and activation of Ras proteins are thought to contribute to the pathological phenotype of stromal fibroblast-like synoviocytes (FLS) in rheumatoid arthritis (RA). Here we examined the expression of each Ras protein in the synovial tissue of patients with RA and disease controls and the contributions of H-, K- and N-Ras homologues to FLS activation in vitro and experimental arthritis in vivo.

Synovial Ras …
FRI0057 Periodontal Disease and Functional Impairment in Rheumatoid Arthritis: Table 1
Authors: J.E. Oller Rodríguez, D. Ybáñez García, E. Valls Pascual, J. Silvestre Rangil, J. Silvestre Donat, I. De la Morena Barrio, E. Vicens Bernabéu, C. Vergara Dangond, Ά. Martínez Ferrer, M. Robustillo Villarino, J.J. Alegre Sancho, F. Gil Latorre
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Several studies have shown a higher degree of periodontal disease (PD) in patients with rheumatoid arthritis (RA) than in general population. This fact could be attributed to the functional impairment caused by the disease. To evaluate this hypothesis, we included disability indicators in this study. <h3>Objectives</h3> To investigate whether the degree of EP is related to functional impairment in patients with RA. <h3>Methods</h3> Transversal study comparing two groups: patients with RA (ACR criteria), and a control group without inflammatory joint disease. At baseline, a rheumatologist performed a clinical examination to RA patients. Within a 20 days period, they were checked by a dentist, who also examined the control group. The variables collected for all subjects included in the study were the following: age, sex, alcohol intake, smoking habit, oral hygiene as measured by the plaque index (PI) and the bleeding index (BI); mean periodontal bursae (MPB), and mean attachment loss (MAL), as markers of periodontitis. We considered the existence of periodontitis if MPB &gt;2 mm and MAL &gt;3 mm. The degree of PD was graded as mild (MAL 1-2 mm), moderate (MAL 3-4 mm), or severe (MAL ≥5), based on the classification of the American Academy of Periodontology. The following data were also compiled for the RA group of patients: degree of activity (DAS28), RF and CCP antibodies positivity, duration of the disease, presence of erosions, association with Sjögren9s Syndrome, treatment (corticosteroids, DMARDs and/or biological therapies), HAQ and Cochin Rheumatoid Arthritis Hand Functional Scale (CRAHFS). The CRAHFS is a questionnaire which measures the degree of hand disability, and includes 18 questions scoring 0-5. We used SPSS 17.0 for descriptive statistics. For inferential statistics, Chi-square, U Mann Whitney and Rho Spearman were used. <h3>Results</h3> A set of 38 RA patients and 40 control subjects were included. We only found differences between both groups in gender (women: 81.6% AR vs. 50% control, p 0.004) and in the PI (the RA patients had poorer oral hygiene than healthy controls, p 0.000). Although we did not found differences in the prevalence of periodontitis, a higher degree of periodontal disease was found in the RA group (p 0.041). We also found a good correlation between the IP, as a marker of oral hygiene, and the HAQ in the RA group, but the correlation with CRAHFS did not reach statistical significance (see Table 1). <h3>Conclusions</h3> The overall functional impairment, and not just hand9s disability, is responsible for a worse oral hygiene and a greater degree of periodontal disease in patients with RA. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4696
Progression to Uremia after Remission of Acute Poststreptococcal Glomerulonephritis
Authors: Robert G. Schacht, Melvin C. Gluck, Gloria R. Gallo, David S. Baldwin
Journal: New England Journal of Medicine (1976)

Whether or not poststreptococcal glomerulonephritis advances over the long term to uremia remains an unsettled issue. We documented ultimate progression to renal failure in six patients who were observed at onset with the typical clinical and morphologic features of acute nephritis after proved betahemolytic streptococcal infection. Within one year, renal function returned essentially to normal in all, as the proliferative changes in glomeruli subsided. Subsequently, increasing renal failure developed in these patients over periods ranging from two to 12 years, during which all were hypertensive. As the renal disease progressed, glomeruli showed increasing sclerosis in the absence of proliferation, and fibrohyaline thickening of renal arterioles appeared. (N Engl J Med 295:977–981, 1976)
Abstract 650: Ex vivo analysis of the mTOR/PI3K &amp; MEK/ERK inhibitors, BEZ235 &amp; AZD6244, alone and in combination in human tumor primary culture micro-spheroids: Exploration of horizontal pathway targeting
Authors: Robert Alan Nagourney, Paula J. Bernard, Federico R. Francisco, Ryan Wexler, Steven S. Evans
Journal: Cancer Research (2011)

Abstract Therapeutic targeting of signal transduction pathways offers fertile ground for the discovery of small molecule kinase inhibitors and novel combinations. The success of Imatinib in CML, the first clinically approved oral TKI, reflects in part, the linear association between the malignant phenotype and c-Abl activation. However, most solid tumors reveal complex interactions between signal pathways that cross talk at points of commonality, the subject of prior report (Nagourney, RA Proc. AACR, 2010). To examine the clinical potential of BEZ235 and AZD6244, inhibitors of the PI3K &amp; MEK/ERK pathways, we applied Ex Vivo Analysis of Programmed Cell Death (EVA/PCD™) (Nagourney RA, Curr. Treat Options in Oncology, 2006) to tumor micro-spheroids isolated from 24 patients. Drugs were tested alone and in combination. Five point dose response curves were interpolated to provide LC50 values. Synergy was assessed by median effect. Activity comparisons were conducted by modified Z-Score. LC50 values by Z-score for AZD revealed Melanoma &amp;gt; Breast &amp;gt; NSCLC &amp;gt; Myeloma &amp;gt;Ovarian &amp;gt; Uterine &amp;gt;Sarcoma &amp;gt; Renal, while BEZ revealed Breast &amp;gt; Renal &amp;gt; NSCLC &amp;gt; Ovarian &amp;gt; Myeloma &amp;gt; Sarcoma &amp;gt; Uterine. By combining BEZ with AZD, we then explored the simultaneous inhibition of the MEK/ERK and PI3K/mTOR pathways. Results in 5 of the first 6 analyses revealed activity &amp; synergy for the dual pathway inhibitor combination. These results support the clinical relevance of targeting the MEK/ERK and PI3K/mTOR pathways and more importantly suggest dual pathway inhibition (horizontal) to be a productive strategy for further clinical developmental. Disease specific profiles and sequence dependence are being explored and will be reported. Supported in part by the Vanguard Cancer Foundation and The Nagourney Institute. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 650. doi:10.1158/1538-7445.AM2011-650
PTU-251 Impact of applying current BSG guidelines on colorectal cancer screening and surveillance colonoscopy procedures
Authors: R Sringeri, M Smith, S de Silva
Journal: Gut (2012)

<h3>Introduction</h3> The demand for colonoscopy is ever increasing, with greater pressures on endoscopy units. In order to provide a more efficient and timely service we conducted a review of our practice. Our aim was to audit colorectal cancer screening and surveillance colonoscopy procedures and determine the impact of the updated BSG guidelines (2010) on service provision.<sup>1</sup> <h3>Methods</h3> The clinical letters, pathology reports and previous endoscopy reports were reviewed for all patients scheduled for surveillance colonoscopy over a period of 3 years (2010–2012). Data gathered included patient demographics, indication for procedure and outcome when audited against the current BSG guidelines. If the procedure did not meet the current guidelines with respect to indication or timing, the responsible clinician contacted both patient and GP, offering a clinic appointment to discuss further if needed. <h3>Results</h3> A total of 354 colonoscopy requests were reviewed. Median age of the group was 62 years (range 22–98 years), male to female ratio 1.7:1. Indications included polyp surveillance 214 (60%), IBD surveillance 55 (15%), family history of colon cancer 50 (14%), high-risk disease and family groups 17 (5%), previous colon cancer 9 (3%) and other indications 9 (3%). 152 (43%) were appropriate when audited against the current guidelines with no changes made to their procedures. Of the remaining 202, 106 (52%) had the time to follow-up procedure extended (mean 3.25 years), 73 (37%) did not meet the criteria for a repeat procedure and 23 (11%) procedures were inappropriately delayed (mean 1.30 yrs). 125 colonoscopy requests were relevant to the updated guidelines for IBD surveillance, family history of colon cancer and high-risk disease and family groups. There were 57 IBD surveillance requests, of which 24 (42%) had the time to follow-up procedure extended (mean 1.75 yrs). Out of 51 requests with family history of colorectal cancer, 23 (45%) had the time to scheduled screening procedure extended (mean 8 yrs). <h3>Conclusion</h3> Evaluating existing colonoscopy referrals against up to date BSG guidelines will contribute towards providing a more efficient colonoscopy service. In our practice a fifth of patients on the waiting list were inappropriate for further surveillance and a further third had the time to their procedure extended, therefore increasing capacity and efficiency to allow timely deliverance of procedures for those needing surveillance. <h3>Competing interests</h3> None declared. <h3>Reference</h3> 1. <b>Cairns S</b>, <i>et al.</i><i>Gut</i> 2010;<b>59</b>:666–90.
Eradication ofHelicobacter pylorireduce disease activity and severity in systemic sclerosis
Authors: Mislav Radić, Dušanka Martinović Kaliterna, Damir Bonacin, Josipa Radić, Damir Fabijanić
Journal: Annals of the Rheumatic Diseases (2012)

<h3>Background</h3> <i>Helicobacter pylori (H pylori)</i> is suspected to be one of the factors triggering systemic sclerosis (SSc). Many reports have emerged describing the pathogenetic potential of <i>H pylori.</i> Data on the possible role of <i>H pylori</i> are lacking. <h3>Objective</h3> The aim of this study was to assess the effect of <i>H pylori</i> eradication in SSc patients. <h3>Methods</h3> Forty-two SSc patients without dyspeptic symptoms were recruited (38 women and 4 men, mean age 54.3±13.6 years, median disease duration 6 years with minimum-maximum range 1–43 years) – 26 were <i>H pylori</i>-positive and 16 were <i>H pylori</i>-negative on the basis of invasive test. The same operator, blind to clinical features, performed upper gastrointestinal endoscopy in all patients. All infected patients were treated successfully. The authors evaluated the disease severity using clinical and laboratory parameters according to a modified Medsger severity scale at baseline and every 6 months during 18 months, and compared the variations in the two subgroups. The level of SSc activity was evaluated before eradication and during a 18 months follow-up period in the similar time intervals. This study was conducted in accordance with the Declaration of Helsinki and its revisions, and the protocol was approved by the Ethics Committee of University Hospital Split. All patients gave informed consent to participate in the study. <h3>Results</h3> After 18 months, <i>H pylori</i>-eradicated SSc patients differed significantly (p&lt;0.05–0.001) from patients without <i>H pylori</i> infection in terms of improvement of skin, muscle and peripheral vascular involvement. At the same time point several laboratory findings (erythrocyte sedimentation rate, antitopoisomerase I antibodies) ahowed significantly lower values (p&lt;0.05) in the <i>H pylori</i>-eradicated subgroup compared to the <i>H pylori</i>-negative subgroup. <i>H pylori</i>-eradicated SSc patients showed progressive improvement over time (p&lt;0.01) of disease severity and activity compared with baseline, whereas <i>H pylori</i>-negative SSc patients remained substantially unchanged. <h3>Conclusion</h3> Our data suggest that <i>H pylori</i> infection is implicated in the SSc pathogenesis and that its eradication may induce a significant impovement of disease severity and activity over 18 months. <i>H pylori</i> eradication seems to be advantageous in infected SSc patients, but further controlled studies are necessary for final conclusion.
Comparison of Renal Transplant Scintigraphy With Renal Resistance Index for Prediction of Early Graft Dysfunction and Evaluation of Acute Tubular Necrosis and Acute Rejection
Authors: Bulent Yazici, Ayse Yazici, Aylin Oral, Aysegül Akgün, Huseyin Toz
Journal: Clinical Nuclear Medicine (2013)

We discuss whether resistance index (RI) and renal scintigraphy obtained within 48 hours after operation could predict the early graft dysfunction. We also aimed to assess the uses of scintigraphy and RI in diagnosis of acute rejection (AR) and acute tubular necrosis (ATN).A total of 153 studies were performed in 109 patients. T½ of perfusion peak, perfusion curve grades, and accumulation index (R20/3) were used as scintigraphic parameters. Baseline studies obtained within 48 hours after transplantation were evaluated for prediction of early graft dysfunction. All data were then assessed for specific diagnosis.Scintigraphic parameters were significantly higher in patients with delayed graft function (DGF) and slow graft function (SGF) than in patients with immediate graft function. These parameters in DGF were also considerably different from those in SGF. The mean RI was significantly high in DGF, but there was no difference between SGF and immediate graft function. In diagnostic groups, the mean values of all tests were significantly different between normal functioning grafts and pathological grafts (ATN + AR). There was no significant difference between AR and ATN. However, renal scintigraphy has higher sensitivity and specificity for AR as compared with RI of Doppler ultrasonography (US).In predicting graft dysfunction and separating normal functioning graft from pathological graft (ATN + AR), renal scintigraphy provides more accurate information than Doppler US. Even though it is superior to Doppler US, renal scintigraphy also cannot reliably separate ATN from AR. The major advantage of renal scintigraphy is the early detection of reduced renal function.
VERY LATE STENT THROMBOSIS AFTER DRUG-ELUTING “CRUSH” AND “MINI-CRUSH” BIFURCATION STENTING IS PREVENTED BY PROLONGED DUAL ANTIPLATELET THERAPY
Authors: Sanjiv Sharma, Rohan Sharma, Neil Bhambi, Brijesh Bhambi, Tetsuo Ishimori
Journal: Journal of the American College of Cardiology (2016)
Acute Lymphedema of the Lower Extremities Revealed by Lymphoscintigraphy
Authors: George S Habib, Walid R Saliba, Carlos Kotler, Simona Ben-Haim
Journal: Clinical Nuclear Medicine (2002)

HABIB, GEORGE S. M.D.*; SALIBA, WALID R. M.D.*; KOTLER, CARLOS M.D.†; BEN-HAIM, SIMONA M.D., D.Sc.‡ Author Information